Abaxis
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Abaxis's revenues will grow 16.3% and EPS will grow 76.9%.
The average estimate for revenue is $48.9 million. On the bottom line, the average EPS estimate is $0.23.
Revenue details
Last quarter, Abaxis booked revenue of $50.0 million. GAAP reported sales were 17% higher than the prior-year quarter's $42.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, EPS came in at $0.30. GAAP EPS of $0.30 for Q4 were 43% higher than the prior-year quarter's $0.21 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 52.4%, 230 basis points worse than the prior-year quarter. Operating margin was 18.0%, 290 basis points better than the prior-year quarter. Net margin was 13.4%, 240 basis points better than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $209.6 million. The average EPS estimate is $1.08.
Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 163 members out of 179 rating the stock outperform, and 16 members rating it underperform. Among 47 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 43 give Abaxis a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Abaxis is hold, with an average price target of $46.13.
Is Abaxis the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Abaxis to My Watchlist.